Literature DB >> 6128385

Identification and measurement of desethylamiodarone in blood plasma specimens from amiodarone-treated patients.

R J Flanagan, G C Storey, D W Holt, P B Farmer.   

Abstract

Desethylamiodarone has been identified as the principal lipophilic metabolite of amiodarone present in plasma specimens from amiodarone-treated patients. This structure has been confirmed by probe-injection mass spectrometry of column effluent fractions and comparison with the authentic compound using both chromatographic and mass spectrometric techniques. Although there is no information available as to the pharmacological activity of desethylamiodarone in man, the plasma concentrations of this metabolite attained during chronic amiodarone therapy are similar to those of the parent compound (0.1-4 mg litre-1).

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6128385     DOI: 10.1111/j.2042-7158.1982.tb04692.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  12 in total

Review 1.  Therapeutic drug monitoring of antiarrhythmic drugs.

Authors:  Gesche Jürgens; Niels A Graudal; Jens P Kampmann
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Development of HepG2-derived cells expressing cytochrome P450s for assessing metabolism-associated drug-induced liver toxicity.

Authors:  Jiekun Xuan; Si Chen; Baitang Ning; William H Tolleson; Lei Guo
Journal:  Chem Biol Interact       Date:  2015-10-22       Impact factor: 5.192

3.  Renal elimination of amiodarone and its desethyl metabolite.

Authors:  L Harris; C R Hind; W J McKenna; C Savage; S J Krikler; G C Storey; D W Holt
Journal:  Postgrad Med J       Date:  1983-07       Impact factor: 2.401

4.  High-performance liquid chromatographic measurement of amiodarone and desethylamiodarone in small tissue samples after enzymatic digestion.

Authors:  G C Storey; P C Adams; R W Campbell; D W Holt
Journal:  J Clin Pathol       Date:  1983-07       Impact factor: 3.411

Review 5.  Clinical pharmacokinetics of amiodarone.

Authors:  R Latini; G Tognoni; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of the newer antiarrhythmic agents.

Authors:  A M Gillis; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Sep-Oct       Impact factor: 6.447

7.  Interaction with the hERG channel and cytotoxicity of amiodarone and amiodarone analogues.

Authors:  K M Waldhauser; K Brecht; S Hebeisen; H R Ha; D Konrad; D Bur; S Krähenbühl
Journal:  Br J Pharmacol       Date:  2008-07-07       Impact factor: 8.739

8.  [Amiodarone therapy--behavior of serum and fatty tissue concentrations].

Authors:  B D Gonska; K P Bethge; H Wagner; K Bosse; J Köbberling; C D Quentin; H Kreuzer
Journal:  Klin Wochenschr       Date:  1986-03-03

9.  Amiodarone kinetics after single i.v. bolus and multiple dosing in healthy volunteers.

Authors:  E Riva; L Aarons; R Latini; P Neyroz; R Urso
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

10.  The role of CYP 3A4 and 1A1 in amiodarone-induced hepatocellular toxicity.

Authors:  Qiangen Wu; Baitang Ning; Jiekun Xuan; Zhen Ren; Lei Guo; Matthew S Bryant
Journal:  Toxicol Lett       Date:  2016-04-22       Impact factor: 4.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.